Amyloid‐Related Imaging Abnormalities in the DIAN‐TU‐001 Trial of Gantenerumab and Solanezumab: Lessons from a Trial in Dominantly Inherited Alzheimer Disease is a research paper published in Annals of Neurology (2022). On theSindex it has a DataRank of 1.8. It has been cited 44 times, with 37 citing works in its 1-hop citation network.
Scored on demand from live citation data
Linked data & code
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.571
From this paper's citation signal
Citation Network Contribution
1.2
From 27 citing papers with measurable signal
Ranked by each citer's contribution to N(p) — log1p(Cq) divided by its reference count — out of 37 citers.
Alzheimer's Association
Grant: AARFD‐20‐681815
Alzheimer's Association
Grant: AARFD‐21‐851415
National Institute on Aging
Grant: R01AG046179
National Institute on Aging
Grant: R01AG053267
National Institute on Aging
Grant: U01AG042791
NIA NIH HHS
Grant: U19 AG032438
NIA NIH HHS
Grant: P30 AG066444
Medical Research Council
Grant: UKDRI-1001
National Institutes of Health
Grant: 3U01AG042791-02S1
DOMINANTLY INHERITED ALZHEIMER NETWORK TRIAL: AN OPPORTUNITY TO PREVENT DEMENTIA
National Institutes of Health
Grant: 5R01AG053267-02
DIAN-TU: Next Generation Prevention Trial
National Institutes of Health
Grant: 5R01AG046179-02
Dominantly Inherited Alzheimer's Network Trials Unit - Adaptive Prevention Trial
Roche
National Institutes of Health
Avid Radiopharmaceuticals
Eli Lilly and Company
FWCI
3.99
Citation Percentile
1.0%
Citation Trend
Fields of Study
MeSH Terms
Keywords
Sustainable Development Goals